Are IDH mutations good minimal residual disease (MRD) markers in acute myeloid leukemia (AML)?
COMy 2017: Day 2 discussion on relapsed myeloma, treatment, plasma cell leukemia and awards
Arnon Nagler et al.
Progress in mantle cell lymphoma over the last 15 years
Why daratumumab is effective in multiple myeloma - results from the CASTOR trial
Why venetoclax is a promising new drug for CLL